Bausch Health posts strong Q3 2026 results, raises full‑year guidance and launches $50 M buyback
Bausch Health Companies reported third‑quarter 2026 revenue of $2.941 billion, a 10% increase year‑over‑year, and adjusted EBITDA of $1.305 billion, up 32%. GAAP net income rose to $436 million, delivering earnings per share of $1.15. The board authorized a $50 million share repurchase program and the company cut net debt by $521 million during the quarter. Management also raised its full‑year 2026 revenue and adjusted EBITDA guidance.
Why it matters
The higher guidance and buyback signal stronger cash generation and confidence in continued growth, which may support the stock price. The debt reduction improves the balance sheet, lowering financial risk for investors.
Key facts
- 1Consolidated reported revenue was $2.941 billion, up 10% versus the prior year period. investing.com
- 2Adjusted EBITDA reached $1.305 billion, a 32% increase year‑over‑year. investing.com
- 3GAAP net income attributable to Bausch Health was $436 million. prnewswire.com
- 4GAAP earnings per diluted share were $1.15. prnewswire.com
- 5The Board authorized a $50 million share repurchase program. prnewswire.com
- 6Net debt was reduced by $521 million, bringing total net debt to $13.132 billion. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.